82 related articles for article (PubMed ID: 29202399)
1. Urokinase receptor derived peptides as potent inhibitors of the formyl peptide receptor type 1-triggered cell migration.
Yousif AM; Ingangi V; Merlino F; Brancaccio D; Minopoli M; Bellavita R; Novellino E; Carriero MV; Carotenuto A; Grieco P
Eur J Med Chem; 2018 Jan; 143():348-360. PubMed ID: 29202399
[TBL] [Abstract][Full Text] [Related]
2. Cyclization of the urokinase receptor-derived ser-arg-ser-arg-tyr Peptide generates a potent inhibitor of trans-endothelial migration of monocytes.
Yousif AM; Minopoli M; Bifulco K; Ingangi V; Di Carluccio G; Merlino F; Motti ML; Grieco P; Carriero MV
PLoS One; 2015; 10(5):e0126172. PubMed ID: 25938482
[TBL] [Abstract][Full Text] [Related]
3. Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity.
Minopoli M; Polo A; Ragone C; Ingangi V; Ciliberto G; Pessi A; Sarno S; Budillon A; Costantini S; Carriero MV
Sci Rep; 2019 Aug; 9(1):12169. PubMed ID: 31434916
[TBL] [Abstract][Full Text] [Related]
4. An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor.
Bifulco K; Longanesi-Cattani I; Gargiulo L; Maglio O; Cataldi M; De Rosa M; Stoppelli MP; Pavone V; Carriero MV
FEBS Lett; 2008 Apr; 582(7):1141-6. PubMed ID: 18339322
[TBL] [Abstract][Full Text] [Related]
5. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide.
Gargiulo L; Longanesi-Cattani I; Bifulco K; Franco P; Raiola R; Campiglia P; Grieco P; Peluso G; Stoppelli MP; Carriero MV
J Biol Chem; 2005 Jul; 280(26):25225-32. PubMed ID: 15866865
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis.
Carriero MV; Longanesi-Cattani I; Bifulco K; Maglio O; Lista L; Barbieri A; Votta G; Masucci MT; Arra C; Franco R; De Rosa M; Stoppelli MP; Pavone V
Mol Cancer Ther; 2009 Sep; 8(9):2708-17. PubMed ID: 19706734
[TBL] [Abstract][Full Text] [Related]
7. The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells.
Ingangi V; Bifulco K; Yousif AM; Ragone C; Motti ML; Rea D; Minopoli M; Botti G; Scognamiglio G; Fazioli F; Gallo M; De Chiara A; Arra C; Grieco P; Carriero MV
Oncotarget; 2016 Aug; 7(34):54474-54487. PubMed ID: 27323409
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion.
Minopoli M; Botti G; Gigantino V; Ragone C; Sarno S; Motti ML; Scognamiglio G; Greggi S; Scaffa C; Roca MS; Stoppelli MP; Ciliberto G; Losito NS; Carriero MV
J Exp Clin Cancer Res; 2019 Nov; 38(1):459. PubMed ID: 31703596
[TBL] [Abstract][Full Text] [Related]
9. A urokinase receptor-derived peptide inhibiting VEGF-dependent directional migration and vascular sprouting.
Bifulco K; Longanesi-Cattani I; Liguori E; Arra C; Rea D; Masucci MT; De Rosa M; Pavone V; Stoppelli MP; Carriero MV
Mol Cancer Ther; 2013 Oct; 12(10):1981-93. PubMed ID: 23939376
[TBL] [Abstract][Full Text] [Related]
10. Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.
Ragone C; Minopoli M; Ingangi V; Botti G; Fratangelo F; Pessi A; Stoppelli MP; Ascierto PA; Ciliberto G; Motti ML; Carriero MV
J Exp Clin Cancer Res; 2017 Dec; 36(1):180. PubMed ID: 29216889
[TBL] [Abstract][Full Text] [Related]
11. Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.
Carriero MV; Bifulco K; Ingangi V; Costantini S; Botti G; Ragone C; Minopoli M; Motti ML; Rea D; Scognamiglio G; Botti G; Arra C; Ciliberto G; Pessi A
Sci Rep; 2017 May; 7(1):1312. PubMed ID: 28465589
[TBL] [Abstract][Full Text] [Related]
12. The soluble form of urokinase receptor promotes angiogenesis through its Ser⁸⁸-Arg-Ser-Arg-Tyr⁹² chemotactic sequence.
Bifulco K; Longanesi-Cattani I; Gala M; DI Carluccio G; Masucci MT; Pavone V; Lista L; Arra C; Stoppelli MP; Carriero MV
J Thromb Haemost; 2010 Dec; 8(12):2789-99. PubMed ID: 20880257
[TBL] [Abstract][Full Text] [Related]
13. Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization.
Genua M; Ingangi V; Fonteyne P; Piontini A; Yousif AM; Merlino F; Grieco P; Malesci A; Carriero MV; Danese S
Inflamm Bowel Dis; 2016 Oct; 22(10):2390-401. PubMed ID: 27537052
[TBL] [Abstract][Full Text] [Related]
14. Role of formic receptors in soluble urokinase receptor-induced human vascular smooth muscle migration.
Duru EA; Fu Y; Davies MG
J Surg Res; 2015 May; 195(2):396-405. PubMed ID: 25758338
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of the N-formyl Peptide receptors in scleroderma fibroblasts fosters the switch to myofibroblasts.
Rossi FW; Napolitano F; Pesapane A; Mascolo M; Staibano S; Matucci-Cerinic M; Guiducci S; Ragno P; di Spigna G; Postiglione L; Marone G; Montuori N; de Paulis A
J Immunol; 2015 Jun; 194(11):5161-73. PubMed ID: 25917089
[TBL] [Abstract][Full Text] [Related]
16.
Napolitano F; Rossi FW; Pesapane A; Varricchio S; Ilardi G; Mascolo M; Staibano S; Lavecchia A; Ragno P; Selleri C; Marone G; Matucci-Cerinic M; de Paulis A; Montuori N
Front Immunol; 2018; 9():574. PubMed ID: 29670612
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Knör S; Sato S; Huber T; Morgenstern A; Bruchertseifer F; Schmitt M; Kessler H; Senekowitsch-Schmidtke R; Magdolen V; Seidl C
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):53-64. PubMed ID: 17891393
[TBL] [Abstract][Full Text] [Related]
18. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
19. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
20. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.
Jacobsen B; Gårdsvoll H; Juhl Funch G; Ostergaard S; Barkholt V; Ploug M
Protein Expr Purif; 2007 Apr; 52(2):286-96. PubMed ID: 17027282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
